Karpilova M A, Durzhinskaya M H
Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021.
Vestn Oftalmol. 2019;135(5. Vyp. 2):299-304. doi: 10.17116/oftalma2019135052299.
Neovascular glaucoma (NVG) is the most frequently occurring type of secondary glaucoma characterized by significant decrease in visual functions. Its pathogenesis consists mainly of ischemia of the posterior segment, which is often secondary to proliferative diabetic retinopathy or ischemic central retinal vein occlusion. Development of neovascularization in the eye is associated with processes that change homeostatic balance between proangiogenic (vascular endothelial growth factor (VEGF)) and antiangiogenic (pigment epithelium-derived factor (PEDF)) factors. The aim of the therapy is to reduce the production of aqueous humour. Application of antiangiogenic preparations in patients with NVG as adjuvant therapy is the method of choice for both prevention and treatment of the disease. The article reviews literature on current possibilities of using anti-VEGF drugs in the treatment of NVG.
新生血管性青光眼（NVG）是最常见的继发性青光眼类型，其特征是视功能显著下降。其发病机制主要由眼后段缺血组成，这通常继发于增殖性糖尿病视网膜病变或缺血性视网膜中央静脉阻塞。眼部新生血管的形成与改变促血管生成（血管内皮生长因子（VEGF））和抗血管生成（色素上皮衍生因子（PEDF））因子之间稳态平衡的过程有关。治疗的目的是减少房水生成。在NVG患者中应用抗血管生成制剂作为辅助治疗是预防和治疗该疾病的首选方法。本文综述了关于使用抗VEGF药物治疗NVG的当前可能性的文献。
